Nuformix loss narrows; near-term goal to focus on NXP002 asset
Nuformix PLC on Monday reported a narrowed annual loss as it made progress on optimising costs and furthering its lead asset, NXP002. Nuformix is a London-based pharmaceutical development company... | May 22, 2023